title: [Chemoimmunoterapy in combination with radiotherapy for treatment of stage III B cervical cancer].
abstract: We wanted to examine the tolerability and the toxicity of the chemoimmunotherapy in combination with radiotherapy in patients with stage III B cervical cancer. Sixteen patients were selected for examination and the experience of the Gynecological Cancer Center in Sidney was summarized as well. We used cisplatin in dose from 10 to 20 mg/m2 intravenously weekly, 5-Fluoruracil/5 Fu/500 mg/m2--24 hours infusion, weekly, interferon-alpha--2a 3MU subcutaneously for 3 days course weekly and 13 cis-retinoic acid 0.5 mg/kg daily by month together with 8 weeks period of radiotherapy after the end of the radiotherapy these medicaments were given for another 4 weeks. According to the dose of the cisplatin medicaments we divided the patients into 3 groups--first group--6 patients with dose to 10 mg/m2 cisplatin, second group--6 patients to 15 mg/m2 cisplatin, third group 4 patients with dose to 20 mg/m2 cisplatin. The patients from the first and second group tolerated the cisplatin. In the third group--4 patients had leucopenia. After the end of chemoimmunotherapy and the patients recovered from the toxicity, they prolonged with radiotherapy. In conclusion from our small experience the cisplatin--15 mg/m2, 5-Fu-500 mg/m2 weekly, interferon alpha--2a 3MU subcutaneously for 3 days course weekly and 13-cis-retinoic acid 0.5 mg/kg daily in combination with radiotherapy for stage III B cervical cancer we can say that and the dose is tolerated extremely well. The leucopenia is the dose-limiting toxicity for this group of patients. The survival rate will be followed. The first results show better survival rate for this group of patients.
authors.forename: Stefan
authors.initials: S
authors.lastname: Ivanov
authors.forename: Stoimen
authors.initials: S
authors.lastname: Ivanov
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D014212:Tretinoin / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014212:Tretinoin; D002945:Cisplatin; D005472:Fluorouracil